You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
AbbVie
since
auto-detected in 12 stories
34 days ago
Drugmaker’s largest deal in more than half a decade comes amid surge of M&A in sector
AbbVie bets $10.9 billion on Apogee in next-generation immunology growth push ⊕
AbbVie said on Monday it would buy biotech Apogee Therapeutics for $10.9 billion, in more than five years.
36 days ago
AbbVie closes in on nearly $11bn deal for biotech Apogee Therapeutics ○
Buyout comes amid an uptick in biotech dealmaking as Big Pharma seeks to bolster its drug pipelines
87 days ago
Here are Thursday's biggest analyst calls: Nvidia, Amazon, Microsoft, Meta, Alphabet, Palantir, AbbVie & more ○
found
Here are the biggest calls on Wall Street on Thursday.
5 months ago
The hidden depths of neurological disease ○
AbbVie SA/NV – BE-ABBV-260011 (V1.0) – January 2026 Disclaimer POLITICAL ADVERTISEMENT More information here.
7 months ago
Decisions today, discoveries tomorrow: Europe’s Choice for the next decade of medicine development ⊕
found
a story from Politico EU ✅ › Politico EU
This article is presented by EFPIA with the support of AbbVie I made a trip back to Europe recently, where I spent the vast majority of my pharmaceutical career, to share my perspectives on competiti…
8 months ago
Healthy Returns: What to expect from Eli Lilly, Merck, Gilead and AbbVie third-quarter earnings ⊕
found
Eli Lilly, Merck, Gilead, Bristol Myers Squibb and AbbVie, among other pharmaceutical companies, are slated to report third-quarter earnings this week.
11 months ago
Trump's pharmaceutical tariffs could affect some drugmakers more than others ○
found
AbbVie, Bristol Myers Squibb and Eli Lilly appear "relatively well-positioned," while Novartis and Roche look more at risk, TD Cowen analyst Steve Scala said.
12 months ago
AbbVie to buy Capstan Therapeutics for up to $2.1 billion ○
13 months ago
Democrats press Pfizer, J&J and others over low tax bills and lobbying as Senate debates Trump's plan ○
found
The lawmakers accuse Pfizer, Merck, J&J, AbbVie and Amgen of paying little to nothing in federal taxes despite generating billions of dollars annually.